DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for nodular sclerosis Hodgkin lymphoma — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNodular sclerosis Hodgkin lymphoma maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for nodular sclerosis hodgkin lymphoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
Abelson helper integration site 1 (AHI1) — AHI1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4ESR · 1.53 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Nodular sclerosis Hodgkin lymphoma is the histological subtype most strongly associated with young adult patients. In a Singapore cohort of 217 Hodgkin lymphoma patients seen between 1990 and 2008, 48% were diagnosed before age 30, and younger patients were significantly more likely to present with the nodular sclerosis subtype (p=0.0001). A 1974 symposium noted a remarkable increase in the incidence of nodular sclerosing Hodgkin disease over the preceding ten years, but attributed this to changing histological criteria rather than an absolute increase in Hodgkin disease overall.
Treatment outcomes for nodular sclerosis Hodgkin lymphoma are drawn from the same Singapore cohort, where 85% of all Hodgkin lymphoma patients received ABVD-based treatment. For early stage disease (stage I/II), 5-year overall survival was 92% and freedom from treatment failure was 93% at 5 years. Among 114 early stage patients, those receiving 4 cycles of ABVD followed by involved field radiotherapy had no difference in overall survival or freedom from treatment failure compared to those receiving 6–8 cycles of ABVD alone (p=0.99 and p=0.48 respectively). However, bulky early stage disease treated with 6 cycles of ABVD plus radiotherapy showed a trend toward better freedom from treatment failure than 4 cycles plus radiotherapy (p=0.06). For advanced stage disease (stage III/IV, n=70), completing 6–8 cycles of ABVD did not benefit from additional radiotherapy even in the presence of bulky disease (n=15). A 1997 case report describes a patient with clinical stage IIA nodular sclerosis Hodgkin disease treated with radiotherapy alone who relapsed after 24 years of complete remission, indicating that very late relapse, though extremely rare, is possible.
Toxicity data from the Singapore cohort show bleomycin-induced pneumonitis occurred in 15% of cases. Neither omission of bleomycin nor the presence of pneumonitis adversely affected treatment outcomes. Haematological malignancies appeared in 1% of survivors after a median of 7.3 years, and hypothyroidism in 3%. What remains missing is prospective data specifically for nodular sclerosis subtype, stratification by tumour bulk in randomised trials comparing abbreviated versus full chemotherapy, and long-term surveillance studies that capture very late relapse patterns beyond the typical 3-year window.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Leukemia & lymphoma/Leukemia and lymphoma · 1997 · 2 citations
Very Late Relapse of Hodgkin's Disease After 24 Years of Complete Remission
AbstractWith current treatment modalities, most patients with early stage Hodgkin's disease (HD) can be cured. Patients destined to relapse, usually do so within 3 years after treatment completion. Late relapses do occur but disease recurrence beyond 15 years is extremely rare. We report a patient with clinical stage IIA nodular sclerosis HD, originally treated with radiotherapy alone, who relapsed 24 years after the initial diagnosis. Our patient's case indicates the possible need for lifelong surveillance of patients with Hodgkin's disease.
Histological Classification of Lymphomas (NISBET SYMPOSIUM, OCTOBER 1972)
AbstractSUMMARY Pathological classification in the group of malignant lymphomas has changed over the past 20 years. The modern classifications of both the Hodgkin's and non‐Hodgkin's lymphomas are presented, together with some relevant historical background. Attention is drawn to the remarkable increase in the incidence of nodular sclerosing Hodgkin's disease in the past ten years, an increase which appears due to changing histological criteria alone, rather than an absolute increase in Hodgkin's disease in general.
Analysis of long-term treatment outcomes and toxicty of HL
Abstracte19536 Background: Prognosis of patients with Hodgkin lymphoma (HL) has substantially improved but therapy of HL can however contribute to delayed toxicity. Long term treatment outcomes of HL in our local population were evaluated. Methods: Clinical and treatment data was prospectively collected from all patients with a histological diagnosis of HL. Patients were all fully staged with CT scan and bone marrow biopsy. Results: On the basis of 217 patients seen at the National Cancer Centre Singapore between 1990–2008, we found that there was a peak in young adulthood with 103 patients who were diagnosed before the age of 30 (48%), median age of presentation 32 (range 17–84). Patients who were young (< 30 years) were more likely to present with nodular sclerosis HL (p=0.0001). Treatment outcomes were comparable to other published series, 85% of cases received ABVD based treatment. 5 year OS for early stage HL was 92% and 88% for advanced stage HL. Overall FFTF was 93% at 5 years. Of note, comparing patients with early stage (Stage I/ II) HL (n=114) who had ABVD 4 cycles followed by involved field radiotherapy (IFRT) with those who received 6–8 cycles of ABVD, there was no difference in OS, FFTF (p= 0.99, 0.48 respectively). Bulky early stage HL who received 6 cycles of ABVD and IFRT had better FFTF rates than those who had just 4 cycles of ABVD followed by IFRT (p=0.06). In contrast, patients patients with advanced HL (Stage III/ IV) (n=70) who completed 6–8 cycles of ABVD did not benefit from additional IFRT even in the presence of bulky disease (n=15). Acute toxicities included that of bleomycin induced pneumonitis (BIP) seen in 15% of cases. Neither the omission of bleomycin nor the presence BIP adversely affected treatment outcomes. Hematological malignancies were seen in 1% of survivors appearing after a median of 7.3 years. Hypothyroidism was noted in 3% of cases. Conclusions: 1) Epidemiology of HL in Singapore is increasingly similar to that of developed countries with a peak in young adults. 2)Young age was predictive of a nodular sclerosis subtype 3) Abbreviated chemotherapy using 4 cycles of ABVD followed by IFRT performed similarly to 6 cycles of ABVD in early stage HL, but in patients with bulky disease this may not be sufficient. 4) BIP occurred in 15% of cases. BIP and the omission of bleomycin did not adversely affect treatment outcomes. No significant financial relationships to disclose.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
